Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Thoracic 4Genitourinary 4Gastrointestinal 3Plasma cell 2Other solid neoplasm 2Myeloid 2Gynecologic 2Breast 2Endocrine 1Dermatologic 1CNS 1

Conditions

EGFR-Mutated Non-Small-Cell Lung Carcinoma 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Electrocardiography × Endocrine × Clear all
NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 11 charts
EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡